Residential College | false |
Status | 已發表Published |
Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer | |
Owen J. Chen1,2; Ester Castellsagué3,4,5; Mohamed Moustafa-Kamal1,2; Javad Nadaf6; Barbara Rivera7,8,9; Somayyeh Fahiminiya3,10; Yilin Wang1,2; Isabelle Gamache1; Caterina Pacifico1,11; Lai Jiang7,12; Jian Carrot-Zhang3,10; Leora Witkowski3,4; Albert M. Berghuis2,13,14; Stefan Schönberger15; Dominik Schneider16; Morten Hillmer17; Susanne Bens17; Reiner Siebert17; Colin J.R. Stewart18; Ziguo Zhang19; William C.H. Chao20; Celia M.T. Greenwood7,12,21; David Barford19; Marc Tischkowitz22; Jacek Majewski3,10; William D. Foulkes3,4,23,24; Jose G. Teodoro1,2,14 | |
2022-10-04 | |
Source Publication | Cancer research |
ISSN | 0008-5472 |
Volume | 82Issue:19Pages:3499-3515 |
Abstract | CDC20 is a coactivator of the anaphase promoting complex/cyclosome (APC/C) and is essential for mitotic progression. APC/CCDC20 is inhibited by the spindle assembly checkpoint (SAC), which prevents premature separation of sister chromatids and aneuploidy in daughter cells. Although overexpression of CDC20 is common in many cancers, oncogenic mutations have never been identified in humans. Using whole-exome sequencing, we identified heterozygous missense CDC20 variants (L151R and N331K) that segregate with ovarian germ cell tumors in two families. Functional characterization showed these mutants retain APC/C activation activity but have impaired binding to BUBR1, a component of the SAC. Expression of L151R and N331K variants promoted mitotic slippage in HeLa cells and primary skin fibroblasts derived from carriers. Generation of mice carrying the N331K variant using CRISPR-Cas9 showed that, although homozygous N331K mice were nonviable, heterozygotes displayed accelerated oncogenicity of Myc-driven cancers. These findings highlight an unappreciated role for CDC20 variants as tumor-promoting genes. |
DOI | 10.1158/0008-5472.CAN-21-3956 |
URL | View the original |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Oncology |
WOS Subject | Oncology |
WOS ID | WOS:000876629600001 |
Publisher | AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 |
Scopus ID | 2-s2.0-85139570709 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Faculty of Health Sciences |
Corresponding Author | William D. Foulkes; Jose G. Teodoro |
Affiliation | 1.McGill University, Montréal, Canada 2.Department of Biochemistry, McGill University, Montréal, Canada 3.Department of Human Genetics, McGill University, Montréal, Canada 4.Division of Medical Genetics and Cancer Axis, Lady Davis Institute, Segal Cancer Centre, Jewish General Hospital, Montréal, Canada 5.Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, L'Hospitalet de Llobregat, Spain 6.McGill University and Génome Québec Innovation Centre, Montréal, Canada 7.Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montréal, Canada 8.Hereditary Cancer Programme, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, Barcelona, L'Hospitalet de Llobregat, Spain 9.Gerald Bronfman Department of Oncology, McGill University, Montréal, Canada 10.Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada 11.Department of Biology, McGill University, Montréal, Canada 12.Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montréal, Canada 13.Centre de Recherche en Biologie Structurale, McGill University, Montréal, Canada 14.Department of Microbiology and Immunology, Montréal, Canada 15.Department of Pediatric Hematology and Oncology, Pediatrics III, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany 16.Clinic of Pediatrics, Dortmund Municipal Hospital, Dortmund, Germany 17.Institute of Human Genetics, University of Ulm & Ulm University Medical Center, Ulm, Germany 18.Department of Histopathology, King Edward Memorial Hospital, School for Women's and Infants' Health, University of Western Australia, Perth, Australia 19.Institute of Cancer Research, London, United Kingdom 20.Faculty of Health Sciences, University of Macau, China 21.Departments of Oncology and Human Genetics, McGill University, Montréal, Canada 22.Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom 23.Program in Cancer Genetics, Department of Oncology and Human Genetics, McGill University, Montréal, Canada 24.Division of Medical Genetics and Cancer Research Program, Research Institute of the McGill University Health Centre, Montréal, Canada |
Recommended Citation GB/T 7714 | Owen J. Chen,Ester Castellsagué,Mohamed Moustafa-Kamal,et al. Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer[J]. Cancer research, 2022, 82(19), 3499-3515. |
APA | Owen J. Chen., Ester Castellsagué., Mohamed Moustafa-Kamal., Javad Nadaf., Barbara Rivera., Somayyeh Fahiminiya., Yilin Wang., Isabelle Gamache., Caterina Pacifico., Lai Jiang., Jian Carrot-Zhang., Leora Witkowski., Albert M. Berghuis., Stefan Schönberger., Dominik Schneider., Morten Hillmer., Susanne Bens., Reiner Siebert., Colin J.R. Stewart., ...& Jose G. Teodoro (2022). Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer. Cancer research, 82(19), 3499-3515. |
MLA | Owen J. Chen,et al."Germline Missense Variants in CDC20 Result in Aberrant Mitotic Progression and Familial Cancer".Cancer research 82.19(2022):3499-3515. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment